474645-27-7 | Monomethyl auristatin e

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$21.00	$15.00
100mg	98%	in stock	$140.00	$98.00
250mg	98%	in stock	$221.00	$155.00
1g	98%	in stock	$628.00	$440.00

Description

• Catalog Number: AB46603
• Chemical Name: Monomethyl auristatin e
• CAS Number: 474645-27-7
• Molecular Formula: C39H67N5O7
• Molecular Weight: 717.9786
• MDL Number: MFCD22124498
• SMILES: CN[C@H](C(=O)NC(=O)[C@@H](N(C([C@@H](CC(=O)N1CCC[C@H]1C([C@H](C(=O)N[C@@H]([C@H](c1ccccc1)O)C)C)OC)OC)[C@H](CC)C)C)C(C)C)C(C)C

Computed Properties

• Complexity: 1100
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 10
• Heavy Atom Count: 51
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 20
• XLogP3: 4.1

Literature

• Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues.

  Analytical chemistry 20120320

• Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

  Molecular pharmaceutics 20120101

• Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

  Cancer journal (Sudbury, Mass.) 20120101

• Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  Current opinion in molecular therapeutics 20100401

• EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

  Journal of the National Cancer Institute 20090902

• Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

  Blood 20090430

• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

  Nature biotechnology 20080801

• Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.

  British journal of haematology 20080701

• Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

  Protein engineering, design & selection : PEDS 20060701

• Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97.

  Molecular cancer therapeutics 20060601

• Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

  Cancer research 20060215

• Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.

  Bioconjugate chemistry 20060101

• Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201